Search
fam-trastuzumab deruxtecan-nxki (Enhertu)
Indications:
- HER2-positive (activating mutation) unresectable or metastatic breast cancer unresponsive to prior chemotherapy
Contraindications:
- pregnancy
Dosage:
- 5.4 mg/kg intravenous every 3 weeks
Adverse effects:
- nausea, leukopenia, anemia, neutropenia, lymphopenia, thrombocytopenia
- decreased serum albumin, increased serum AST, increased serum ALT
- increased serum alkaline phosphatase
- fatigue, constipation, anorexia, vomiting, alopecia
Notes:
- distinguish from trastuzumab (Herceptin) with different dosage & treatment schedules [3]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
trastuzumab (Herceptin, Herzuma, CT-P6)
References
- FDA Approved drugs. 2022. August 2022
FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant
non-small cell lung cancer.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Enhertu: fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s021lbl.pdf
- FDA MedWarch. May 6, 2013
Kadcyla (ado-trastuzumab emtansine): Drug Safety Communication
- Potential Medication Errors Resulting from Name Confusion.
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350817.htm